Zobrazeno 1 - 10
of 140
pro vyhledávání: '"Philip S. Insel"'
Autor:
Christina B. Young, Emily Johns, Gabriel Kennedy, Michael E. Belloy, Philip S. Insel, Michael D. Greicius, Reisa A. Sperling, Keith A. Johnson, Kathleen L. Poston, Elizabeth C. Mormino, for the Alzheimer’s Disease Neuroimaging Initiative, the A4 Study Team
Publikováno v:
Molecular Neurodegeneration, Vol 18, Iss 1, Pp 1-14 (2023)
Abstract Background APOE variants are strongly associated with abnormal amyloid aggregation and additional direct effects of APOE on tau aggregation are reported in animal and human cell models. The degree to which these effects are present in humans
Externí odkaz:
https://doaj.org/article/3bee54045fa448f4900aab27548666cc
Autor:
Isadora Lopes Alves, Fiona Heeman, Lyduine E. Collij, Gemma Salvadó, Nelleke Tolboom, Natàlia Vilor-Tejedor, Pawel Markiewicz, Maqsood Yaqub, David Cash, Elizabeth C. Mormino, Philip S. Insel, Ronald Boellaard, Bart N. M. van Berckel, Adriaan A. Lammertsma, Frederik Barkhof, Juan Domingo Gispert
Publikováno v:
Alzheimer’s Research & Therapy, Vol 13, Iss 1, Pp 1-13 (2021)
Abstract Background Detecting subtle-to-moderate biomarker changes such as those in amyloid PET imaging becomes increasingly relevant in the context of primary and secondary prevention of Alzheimer’s disease (AD). This work aimed to determine if an
Externí odkaz:
https://doaj.org/article/082c31a7af464c6799346086b3dce7a1
Autor:
Maurits Johansson, Erik Stomrud, Philip S. Insel, Antoine Leuzy, Per Mårten Johansson, Ruben Smith, Zahinoor Ismail, Shorena Janelidze, Sebastian Palmqvist, Danielle van Westen, Niklas Mattsson-Carlgren, Oskar Hansson
Publikováno v:
Translational Psychiatry, Vol 11, Iss 1, Pp 1-8 (2021)
Abstract Mild behavioral impairment (MBI) is suggested as risk marker for neurodegenerative diseases, such as Alzheimer’s disease (AD). Recently, pathologic tau deposition in the brain has been shown closely related to clinical manifestations, such
Externí odkaz:
https://doaj.org/article/b75710a3e7de4aef8b90a01f1fb01621
Autor:
Nicholas C. Cullen, Henrik Zetterberg, Philip S. Insel, Bob Olsson, Ulf Andreasson, the Alzheimer’s Disease Neuroimaging Initiative, Kaj Blennow, Oskar Hansson, Niklas Mattsson‐Carlgren
Publikováno v:
Annals of Clinical and Translational Neurology, Vol 7, Iss 9, Pp 1661-1673 (2020)
Abstract Objective To investigate the statistical power of plasma, imaging, and cognition biomarkers as Alzheimer’s disease (AD) clinical trial outcome measures. Methods Plasma neurofilament light, structural magnetic resonance imaging, and cogniti
Externí odkaz:
https://doaj.org/article/6aac7c2958e143a484d74e78928e9158
Publikováno v:
Annals of Clinical and Translational Neurology, Vol 7, Iss 5, Pp 776-785 (2020)
Abstract Objective To clarify the preclinical stage of Alzheimer’s disease by estimating when β‐amyloid accumulation first becomes associated with changes in cognition. Methods Here we studied a large group (N = 4432) of cognitively unimpaired i
Externí odkaz:
https://doaj.org/article/10c05809c4a04501ae3b892e951aeacd
Autor:
Rachel L. Nosheny, Chengshi Jin, John Neuhaus, Philip S. Insel, Robert Scott Mackin, Michael W. Weiner, Alzheimer’s Disease Neuroimaging Initiative investigators
Publikováno v:
Annals of Clinical and Translational Neurology, Vol 6, Iss 12, Pp 2448-2459 (2019)
Abstract Objective Identifying individuals at risk for cognitive decline, Mild Cognitive Impairment (MCI), and dementia due to Alzheimer’s disease (AD) is a critical need. Functional decline is associated with risk and can be efficiently assessed b
Externí odkaz:
https://doaj.org/article/b488f799435b4989ad20ea70afa1304b
Publikováno v:
NeuroImage, Vol 227, Iss , Pp 117676- (2021)
Objective: Estimate the time-course of the spread of key pathological markers and the onset of cognitive dysfunction in Alzheimer's disease. Methods: In a cohort of 335 older adults, ranging in cognitive functioning, we estimated the time of initial
Externí odkaz:
https://doaj.org/article/9878de3bc0db4ad7841e564627490a1d
Autor:
R. Scott Mackin, Philip S. Insel, Diana Truran, Shannon Finley, Derek Flenniken, Rachel Nosheny, Aaron Ulbright, Monica Comacho, David Bickford, Brian Harel, Paul Maruff, Michael W. Weiner
Publikováno v:
Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, Vol 10, Iss 1, Pp 573-582 (2018)
Abstract Introduction The purpose of this study is to compare online neuropsychological test performance of older adults across self‐reported diagnoses of being cognitively normal, mild cognitive impairment, and dementia due to Alzheimer's disease
Externí odkaz:
https://doaj.org/article/f45d616cc9fe4211a276075c4e9ba8f1
Autor:
Ronald Lautner, Philip S. Insel, Tobias Skillbäck, Bob Olsson, Mikael Landén, Giovanni B. Frisoni, Sanna-Kaisa Herukka, Harald Hampel, Anders Wallin, Lennart Minthon, Oskar Hansson, Kaj Blennow, Niklas Mattsson, Henrik Zetterberg
Publikováno v:
Alzheimer’s Research & Therapy, Vol 9, Iss 1, Pp 1-7 (2017)
Abstract Background From earlier studies it is known that the APOE ε2/ε3/ε4 polymorphism modulates the concentrations of cerebrospinal fluid (CSF) beta-amyloid1–42 (Aβ42) in patients with cognitive decline due to Alzheimer’s disease (AD), as
Externí odkaz:
https://doaj.org/article/67b4911748414c20b9b1a7a2bd0dd04e
Autor:
Niklas Mattsson, Philip S. Insel, Sebastian Palmqvist, Erik Stomrud, Danielle van Westen, Lennart Minthon, Henrik Zetterberg, Kaj Blennow, Oskar Hansson
Publikováno v:
Nature Communications, Vol 7, Iss 1, Pp 1-7 (2016)
Autosomal dominant Alzheimer's disease is thought to be caused by increased amyloidogenic APP processing. Mattson et al.show that association between brain Aβ and cerobrospinal fluid Aβ40 levels is stronger in APOE ɛ4 negative people, suggesting t
Externí odkaz:
https://doaj.org/article/44a4c2bf90d84c7db136699be8a9a557